{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-462199","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2026-11-16T13:15:21+00:00","discovered_at":"2026-11-16T13:20:32.733620+00:00","generated_at":"2026-11-16T13:20:50.238276+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CG Oncology PIVOT-006 Phase 3 wins: 68% recurrence risk cut (HR 0.32) in NMIBC","bullets":["Cretostimogene cut recurrence risk 68% vs control in adjuvant intermediate-risk/high-grade Ta ≤3cm NMIBC; HR 0.32 (95% CI 0.23-0.45; p<0.0001), median follow-up 17 months.","No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations; safety consistent with prior studies.","Initial BLA in BCG-unresponsive NMIBC broadened per FDA feedback to include high-grade papillary-only disease plus CIS; completion now expected by end of March 2027.","Second BLA in intermediate-risk and high-grade Ta NMIBC planned for Q2 2027; ~50,000 US patients in this population have no FDA-approved adjuvant option.","Topline results to be presented as a late-breaking podium at the Society of Urologic Oncology Annual Meeting on December 2, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-462199","json":"https://secwatch.observer/filing/0001193125-26-462199.json","markdown":"https://secwatch.observer/filing/0001193125-26-462199.md","text":"https://secwatch.observer/filing/0001193125-26-462199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/0001193125-26-462199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/ck0001991792-20261116.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-16T13:20:50.238276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}